



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref:Corp.sec/2023-24/BSE/97

Dated:17.10.2023

To,

The Deputy Manager (Corporate Services)
The Bombay Stock Exchange Limited
1st Floor, Rotunda Bldg
B.S Marg , Fort
Mumbai -400001

Sub: Reconciliation of Share Capital Audit Report as Regulation 76 of SEBI (Depositories and Participant) Regulations, 2018 for the Quarter ended 30TH September 2023.

Sir,

We are sending herewith Reconciliation of Share Capital Audit Report as per the Regulation 76 of SEBI (Depositories and Participant) Regulations, 2018 for the Quarter ended on 30th September 2023.

Kindly take note of the same.

For Sandu Pharmaceuticals Limited

Pratika Mhambray
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



ND & ASSOCIATES

Practising Company Secretaries

Neeta H. Desai

BA, LLB, LLM, FCS
Tel : 02224095104
Mobile: 09821498216
Mobile: 09892288254



279/18 Shantikunj, Road No. 31
Sion East, Mumbai – 400022
E-mail: ndassociates2128@gmail.com
E-mail: ndassociates@rediffmail.com

RECONCILIATION OF SHARE CAPITAL AUDIT

(As per regulation 76 of the SEBI (Depositories and Participants) Regulation, 2018)

1	For Quarter Ended	30 th September 2023																
2	ISIN :	INE 751D01014																
3	Face Value :	Rs. 10/- each																
4	Name of the Company	Sandu Pharmaceuticals Limited.																
5	Registered Office Address	Plot No. 25,26,29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511																
6	Correspondence Address	Plot No. 25,26,29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511																
7	Telephone & Fax No.	Tel:0832-2407473/74 Fax:0832-2407008																
8	Email address	corp.sec@sandu.in																
9	Names of the Stock Exchanges where the company's securities are listed:	Mumbai Stock Exchange																
		<table border="1"><thead><tr><th>Number of Shares</th><th>% of Total Issued Capital</th></tr></thead><tbody><tr><td>9660990</td><td>-----</td></tr><tr><td>BSE: 9660990</td><td>-----</td></tr><tr><td>30.09.2023</td><td>%</td></tr><tr><td>7185012</td><td>74.37</td></tr><tr><td>1621728</td><td>16.79</td></tr><tr><td>854250</td><td>08.84</td></tr><tr><td>9660990</td><td>100 %</td></tr></tbody></table>	Number of Shares	% of Total Issued Capital	9660990	-----	BSE: 9660990	-----	30.09.2023	%	7185012	74.37	1621728	16.79	854250	08.84	9660990	100 %
Number of Shares	% of Total Issued Capital																	
9660990	-----																	
BSE: 9660990	-----																	
30.09.2023	%																	
7185012	74.37																	
1621728	16.79																	
854250	08.84																	
9660990	100 %																	
10	Issued Capital																	
11	Listed Capital (Exchange wise) (as per company records)																	
12	Held in dematerialized form in NSDL																	
13	Held in dematerialized form in CDSL																	
14	Physical																	
15	Total No. of shares (12+13+14)																	
16	Reasons for difference if any, between (10&11), (10&15), (11&15):	NA																
17	Certifying the details of changes in share capital during the quarter under consideration as per Table below:	NA																

Particulars	No of shares/warrants	Applied / Not applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. appr. pending for SE (Specify Names)
--	---	--	--	--	--	--
--	--	--	--	--	--	--

* Rights, Bonus, Preferential issue, ESOPs/ Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18	Register of Members is updated (Yes / No) If not, updated up to which date	Yes -----
19	Reference of previous quarter with regards to excess Dematerialized shares, if any.	N. A
20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason for delay:	N. A
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :	

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 days	---	---	---
Pending for more than 21 days	---	---	---
22	Name, Telephone & Fax No. of the Compliance Officer of the Co.	Mrs. Pratika P. Mhambray (Company Secretary & Compliance Officer) Tel:0832-2407473/74 Fax:0832-2407008	
23	Name, Address, Tel. & Fax No., Regn. No. of the Auditor	Neeta H. Desai 279/18, Shantikunj, Sion (E), Road No. 31, Mumbai – 400 022. C. P. No. 4741, Tel: 24095104	
24	Appointment of common agency for share registry work (if yes (name & address)	Link Intime India Private Ltd C-101, 247 Park, L B S Marg, Vikhroli West, Mumbai 400083	
25	Any other detail that the auditor may like to provide	<p>The Company had made an application under the provision of Regulation 31A of SEBI (LODR) Regulation 2015 for seeking reclassification of promoter shareholders vide a letter dated October 28, 2021. The application was approved by BSE vide letter number LIST/COMP/HN/401/2023-2024 dated 16th August 2023</p> <p>The above certificate is issued based on the electronic data provided by the Company.</p>	

Note:

The above certificate is issued based on the Register of Members, beneficiary details and other documents furnished by the Company and its Share Transfer Agents M/s. Link Intime India Private Limited and also the explanation given to us.

Place: Mumbai**Date: 16.10.2023****UDIN: F003262E001322657****For ND & Associates**

NEETA
HARKISHAN
DESAI

Neeta H. Desai
Company Secretary
C P No. 4741

Digitally signed by NEETA HARKISHAN DESAI
DN: cn=NEETA HARKISHAN DESAI, o=NEETA HARKISHAN DESAI, email=neeta@neeta.com, c=IN
Date: 2023.10.16 14:46:45 +05'30'